Marta López-Yus

Dr. Marta López-Yus


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2024 in Journal of Physiology and Biochemistry
Verified
Journal Article
Open access
PDF file
SQSergio Quesada-Vázquez
Sergio Quesada-Vázquez
IEItziar Eseberri
Itziar Eseberri
FLFrancisco Les
Francisco Les
PPPatricia Pérez-Matute
Patricia Pérez-Matute
MHMaría Herranz-López
María Herranz-López
CCChristian Carpéné
Christian Carpéné
A diet rich in polyphenols and other types of phytonutrients can reduce the occurrence of chronic diseases. However, a well-established cause—and—effect association has not been clearly demonstrated and several other issues will need to be fully understood before general recommendations will be carried out In the present review, some of the future challenges that the research on phenolic compounds will have to face in the next years are discussed: toxicological aspects of polyphenols and safety risk assessment; synergistic effects between different polyphenols; metabotype-based nutritional advice based on a differential gut microbial metabolism of polyphenols (precision nutrition); combination of polyphenols with other bioactive compounds; innovative formulations to improve the bioavailability of phenolic compounds; and polyphenols in sports nutrition and recovery.Other aspects related to polyphenol research that will have a boost in the next years are: polyphenol and gut microbiota crosstalk, including prebiotic effects and biotransformation of phenolic compounds into bioactive metabolites by gut microorganisms; molecular docking, molecular dynamics simulation, and quantum and molecular mechanics studies on the protein–polyphenol complexes; and polyphenol-based coating films, nanoparticles, and hydrogels to facilitate the delivery of drugs, nucleic acids and proteins.In summary, this article provides some constructive inspirations for advancing in the research of the applications, risk assessment and metabolic effects of dietary polyphenols in humans.

22 February 2024 in Cells
Verified
Journal Article
Open access
PDF file
MLMarta López-Yus
Marta López-Yus
CHCarlos Hörndler
Carlos Hörndler
SBSOFIA sofia BORLAN
SOFIA sofia BORLAN
VBVanesa Bernal
Vanesa Bernal
José Miguel Arbones-MainarJosé Miguel Arbones-Mainar
José Miguel Arbones-Mainar
Adipose tissue (AT), once considered a mere fat storage organ, is now recognized as a dynamic and complex entity crucial for regulating human physiology, including metabolic processes, energy balance, and immune responses. It comprises mainly two types: white adipose tissue (WAT) for energy storage and brown adipose tissue (BAT) for thermogenesis, with beige adipocytes demonstrating the plasticity of these cells. WAT, beyond lipid storage, is involved in various metabolic activities, notably lipogenesis and lipolysis, critical for maintaining energy homeostasis. It also functions as an endocrine organ, secreting adipokines that influence metabolic, inflammatory, and immune processes. However, dysfunction in WAT, especially related to obesity, leads to metabolic disturbances, including the inability to properly store excess lipids, resulting in ectopic fat deposition in organs like the liver, contributing to non-alcoholic fatty liver disease (NAFLD). This narrative review delves into the multifaceted roles of WAT, its composition, metabolic functions, and the pathophysiology of WAT dysfunction. It also explores diagnostic approaches for adipose-related disorders, emphasizing the importance of accurately assessing AT distribution and understanding the complex relationships between fat compartments and metabolic health. Furthermore, it discusses various therapeutic strategies, including innovative therapeutics like adipose-derived mesenchymal stem cells (ADMSCs)-based treatments and gene therapy, highlighting the potential of precision medicine in targeting obesity and its associated complications.

Verified
Journal Article
Open access
PDF file
MLMarta López-Yus
Marta López-Yus
MSMARIA PILAR GARCIA SOBREVIELA
MARIA PILAR GARCIA SOBREVIELA
RBRAQUEL del Moral Bergós
RAQUEL del Moral Bergós
José Miguel Arbones-MainarJosé Miguel Arbones-Mainar
José Miguel Arbones-Mainar
Obesity is a highly prevalent condition often associated with dysfunctional adipose tissue. Stem cell-based therapies have become a promising tool for therapeutic intervention in the context of regenerative medicine. Among all stem cells, adipose-derived mesenchymal stem cells (ADMSCs) are the most easily obtained, have immunomodulatory properties, show great ex vivo expansion capacity and differentiation to other cell types, and release a wide variety of angiogenic factors and bioactive molecules, such as growth factors and adipokines. However, despite the positive results obtained in some pre-clinical studies, the actual clinical efficacy of ADMSCs still remains controversial. Transplanted ADMSCs present a meager rate of survival and proliferation, possibly because of the damaged microenvironment of the affected tissues. Therefore, there is a need for novel approaches to generate more functional ADMSCs with enhanced therapeutic potential. In this context, genetic manipulation has emerged as a promising strategy. In the current review, we aim to summarize several adipose-focused treatments of obesity, including cell therapy and gene therapy. Particular emphasis will be given to the continuum from obesity to metabolic syndrome, diabetes, and underlying non-alcoholic fatty liver disease (NAFLD). Furthermore, we will provide insights into the potential shared adipocentric mechanisms involved in these pathophysiological processes and their remediation using ADMSCs.

25 October 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
SESilvia Espina
Silvia Espina
YGYolanda Gonzalez-Irazabal
Yolanda Gonzalez-Irazabal
ASAlejandro Sanz-Paris
Alejandro Sanz-Paris
MLMarta López-Yus
Marta López-Yus
MSMARIA PILAR GARCIA SOBREVIELA
MARIA PILAR GARCIA SOBREVIELA
José Miguel Arbones-MainarJosé Miguel Arbones-Mainar
José Miguel Arbones-Mainar
Low plasma levels of branched chain amino acids (BCAA) in liver cirrhosis are associated with hepatic encephalopathy (HE). We aimed to identify a metabolic signature of minimal hepatic encephalopathy (MHE) in malnourished cirrhotic patients and evaluate its modification with oral nutritional supplements (ONS) enriched with ß-Hydroxy-ß-methylbutyrate (HMB), a derivative of the BCAA leucine. Post hoc analysis was conducted on a double-blind placebo-controlled trial of 43 individuals with cirrhosis and malnutrition, who were randomized to receive, for 12 weeks, oral supplementation twice a day with either 220 mL of Ensure® Plus Advance (HMB group, n = 22) or with 220 mL of Ensure® Plus High Protein (HP group, n = 21). MHE evaluation was by psychometric hepatic encephalopathy score (PHES). Compared to the HP group, an HMB-specific treatment effect led to a larger increase in Val, Leu, Phe, Trp and BCAA fasting plasma levels. Both treatments increased Fischer’s ratio and urea without an increase in Gln or ammonia fasting plasma levels. MHE was associated with a reduced total plasma amino acid concentration, a reduced BCAA and Fischer´s ratio, and an increased Gln/Glu ratio. HMB-enriched ONS increased Fischer´s ratio without varying Gln or ammonia plasma levels in liver cirrhosis and malnutrition, a protective amino acid profile that can help prevent MHE.

Verified
Journal Article
Open access
PDF file
IMIgnacio Colón Mesa
Ignacio Colón Mesa
Marta Fernández GalileaMarta Fernández Galilea
Marta Fernández Galilea
NSNeira Sáinz
Neira Sáinz
MLMarta López-Yus
Marta López-Yus
JAJose M. Artigas
Jose M. Artigas
MMMaria J. Moreno-Aliaga
Maria J. Moreno-Aliaga
Aging usually comes associated with increased visceral fat accumulation, reaching even an obesity state, and favoring its associated comorbidities. One of the processes involved in aging is cellular senescence, which is highly dependent on the activity of the regulators of the cell cycle. The aim of this study was to analyze the changes in the expression of p27 and cdk2 in different adipose tissue depots during aging, as well as their regulation by obesity in mice. Changes in the expression of p27 and CDK2 in visceral and subcutaneous white adipose tissue (WAT) biopsies were also analyzed in a human cohort of obesity and type 2 diabetes. p27, but not cdk2, exhibits a lower expression in subcutaneous than in visceral WAT in mice and humans. p27 is drastically downregulated by aging in subcutaneous WAT (scWAT), but not in gonadal WAT, of female mice. Obesity upregulates p27 and cdk2 expression in scWAT, but not in other fat depots of aged mice. In humans, a significant upregulation of p27 was observed in visceral WAT of subjects with obesity. Taken together, these results show a differential adipose depot-dependent regulation of p27 and cdk2 in aging and obesity, suggesting that p27 and cdk2 could contribute to the adipose-tissue depot’s metabolic differences. Further studies are necessary to fully corroborate this hypothesis.

Verified
Journal Article
Open access
PDF file
JMJavier Sánchez Marco
Javier Sánchez Marco
CCCRISTINA BARRANQUERO CORTES
CRISTINA BARRANQUERO CORTES
RBRoberto Martínez Beamonte
Roberto Martínez Beamonte
JMJoaquín Carlos Surra Muñoz
Joaquín Carlos Surra Muñoz
Seyed Hesamoddin BidookiSeyed Hesamoddin Bidooki
Seyed Hesamoddin Bidooki
Jesus OsadaJesus Osada
Jesus Osada
Thioredoxin domain-containing protein 5 (TXNDC5) plays a role in diseases related to oxidative stress, energy metabolism, and cellular inflammation. This protein has also been associated with diabetes and insulin folding. To gain insight into these relationships, glucose metabolism was characterized using Txndc5-deficient mice. The absence of TXNDC5 lowered glycemia, which was correlated with higher non-esterified fatty acid (NEFA) levels following an overnight fast on a chow diet in males. Several tolerance tests (pyruvate, glucose, and insulin) revealed no impairment in gluconeogenesis, but rather, higher insulin sensitivity. In vitro assays using an engineered hepatic cell line corroborated the results of increased glucose uptake. When a high-fat, high-sucrose diet was administered to induce a prediabetic state, the absence of TXNDC5 reproduced the lower glycemia and higher NEFA levels observed in mice consuming the chow diet. However, higher levels of plasma insulin were observed in Txndc5-deficient mice. The insulin receptor was increased in the hepatic plasma membranes. Increased hepatic gene expression of G6pc, Irs2, and Igfbp1 was also observed in the absence of TXNDC5. These results indicate that TXNDC5 plays a role in the hepatic sex-differential handling of glucose and lipids, and in retaining the insulin receptor on the plasma membrane.